Caplin Point Laboratories Ltd.
NSE: CAPLIPOINTCaplin Point Laboratories Ltd.: A 30-second snapshot
Caplin Point trades at 2501.9, up 23.24% over the past year and 43.95% over the past 3 months, above both its 50-DMA (2401.87) and 200-DMA (1967.16) with RSI at a neutral 48.36. ROE stands at 19.94%, profit margin at 29.32%, and debt/equity at 0.127 on a falling trend, with 4 consecutive years of positive free cash flow.
P/E
29.7
Forward P/E
23.4
ROE
+19.9%
Debt / Equity
0.13
Profit Margin
+29.3%
Div. Yield
+0.3%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
75/100
News
2 headlines · 0 positive · 0 negative
Recent context
- ·An Aug 12 earnings call for Q1 results was flagged in a Jul 30 report, ahead of which the stock has already advanced 43.95% over the trailing 3 months.
- ·Coverage over Jul 20-30 is limited to two neutral wire items, one referencing forward enterprise-value-to-revenue.
- ·The stock trades 7.3% below its 52-week high after the 3-month advance, with RSI at a neutral 48.36 rather than an extended reading.
Strengths
- +ROE of 19.94% with 4 years above the 15% threshold and a persistence/consistency score of 92, alongside a profit margin of 29.32%.
- +Debt/equity of 0.127 on a falling trend, with free cash flow positive in 4 of the recent tracked years.
- +5-year revenue growth of 19% closely tracks 5-year earnings growth of 19.4%.
- +Ranks 1st of 6 sector peers on quality score, and 2nd of 6 on both PE (29.73) and ROE (19.94%).
Weaknesses
- −3-month price return of 43.95% substantially exceeds the 1-year return of 23.24%, indicating the bulk of the annual gain is concentrated in the most recent quarter.
- −Current price of 2501.9 sits just above the nearest identified support level of 2501.6, leaving limited cushion before the next support at 2435.4.
- −Analyst coverage is limited to 2 analysts and news coverage over the sampled period is limited to 2 neutral articles, restricting the depth of external validation available.
- −Sector peer comparison data is incomplete: ROE is missing for Cipla and 1-year price-change is missing for all 5 listed peers, limiting how conclusively relative valuation can be assessed.
Open questions
- ?Is the concentration of the annual price gain within the most recent 3 months tied to a specific identifiable catalyst, or part of a broader move across pharma peers?
- ?How does the falling debt/equity trend align with the capital needs of continued U.S./LATAM market expansion the company has pursued historically?
- ?Given ROE and 1-year price-change data is unavailable for most listed peers, what additional peers or benchmarks would provide a more complete relative-valuation picture?
- ?Does the upcoming Aug 12 earnings call offer clarity on whether the 19%/19.4% revenue and earnings growth trajectory continues into the next fiscal year?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| CAPLIPOINT | Caplin Point Laboratories Ltd.You're viewing | 29.7 | +19.9% | 65 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 42.1 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.2 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.8 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.8 | +8.8% | 4 |
Technical state
Current price
₹2,501.90
SMA 50
₹2,401.87
SMA 200
₹1,967.16
RSI (14)
48.4 (neutral)
From 52w high
-7.3%
1Y return
+23.2%
3M return
+44.0%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- medium3-month price return (43.95%) is nearly double the 1-year return (23.24%), implying the stock declined over months 3-12 before a sharp recent rally; price now trades 27% above its 200-DMA (1967.16).
- mediumCurrent price (2501.9) sits just 0.3 points above the nearest identified support level (2501.6), effectively testing that pivot, with the next support at 2435.4 (2.7% lower).
- lowNews coverage over the sampled period is sparse: only 2 articles, both neutral, providing no positive or negative sentiment signal to corroborate the recent price move.
- lowAnalyst coverage is minimal (2 analysts on the 1-5 scale) and sector peer comparison data is incomplete: ROE is missing for 1 of 5 peers, and 1-year price-change is missing for all 5, limiting the reliability of relative valuation conclusions.
Cross-section contradictions
- 3-month price return (43.95%) is nearly double the 1-year return (23.24%), while news coverage over the same window is limited to 2 neutral articles, leaving the rally without a visible news catalyst in the sample captured.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 31 Jul 2026 · rotates through NIFTY 500 every ~5 days